Brief: Renovorx Receives New 510(K) Clearance For Its Renovocath Delivery System Designed For Targeted Treatment Of Solid Tumors
07/09/2021 11:47
Sept 7 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX RECEIVES NEW 510(K) CLEARANCE FOR ITS RENOVOCATH®
DELIVERY SYSTEM DESIGNED FOR TARGETED TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nPn5Ckc2Xa
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies